uniQure to Participate in Multiple Upcoming Industry Conferences
May 01, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress
April 29, 2019 07:00 ET
|
uniQure Inc.
~ Presented Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B Demonstrating Increases in FIX Activity Sustained at up to 51% of Normal at 12 Weeks ~ Achieved IND...
uniQure to Participate in Multiple Upcoming Industry Conferences
March 29, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 29, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences
March 01, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
February 28, 2019 07:00 ET
|
uniQure Inc.
~ Initiated Dosing Phase of HOPE-B Pivotal Study of AMT-061 in Hemophilia B ~ ~ Reported Updated Clinical Data from Phase IIb Study of AMT-061 Demonstrating Sustained FIX Activity at up to 51% of...
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
November 19, 2018 12:15 ET
|
uniQure Inc.
~ Unveils New AAV Gene Therapy Approaches to Hemophilia A, Fabry Disease and Spinocerebellar Ataxia Type 3 ~ ~ Introduces miQURE™ Gene Silencing Platform with Applications Across Multiple Indications...
uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress
November 06, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences
October 31, 2018 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies
October 18, 2018 06:55 ET
|
uniQure Inc.
~ New Data Presented at the European Society of Gene and Cell Therapy Annual Meeting Demonstrates up to 40 Times Higher Liver Expression with Optimized Promoter ~ LEXINGTON, Mass. and AMSTERDAM, the...
uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 17, 2018 07:00 ET
|
uniQure Inc.
~ Commercial Capacity for AAV Gene Therapy Production Significantly Enhanced by Highly Scalable 500 Liter Reactors ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 17, 2018 (GLOBE NEWSWIRE)...